# Pharmaceutical Strategies Group

> Pharmaceutical Strategies Group (PSG), an EPIC company, advises U.S. employers, health plans, health systems and labor unions on pharmacy benefits. It combines PBM consulting, audits and implementation support with Artemetrx software that integrates pharmacy and medical claims to identify spending opportunities and monitor contractual performance.

- **Founded:** 1994
- **Headquarters:** Dallas, United States
- **Founders:** Dave Borden (Founder of PSG in 2003; acquired AELRx in 2004), Don Lea (Founder of predecessor AELRx in 1994)
- **Products:** Pharmacy Benefits Consulting, Artemetrx Core, Artemetrx Diagnostic, Artemetrx Extend, Artemetrx Plus
- **Notable:** Reported fourth consecutive Inc. 5000 appearance in August 2020., Sold its 340B Link business to Omnicell for $225 million in October 2020; this is a business divestiture, not PSG’s current valuation., Current homepage reports $10.7 billion in drug cost savings over the last two years; company-reported aggregate.

## Products & services

- **Pharmacy Benefits Consulting** — PBM procurement, contracting, market checks, clinical optimization, performance reviews and government-program support.
- **Artemetrx Core** — Web-based integrated medical and pharmacy claims analytics, dashboards and clinical utilization rules.
- **Artemetrx Diagnostic** — Drug-spending assessment with recommendations on treatment, high-cost populations and sites of care.
- **Artemetrx Extend** — Custom reporting interface for exploring plan data.
- **Artemetrx Plus** — Clinical consulting paired with Artemetrx analytics.
- **Artemetrx Pricing Monitor** — Continuous comparison of PBM pricing performance against contractual guarantees.
- **Artemetrx Rebate Monitor** — Expected-versus-paid rebate analysis using claims and contract rules.
- **Artemetrx GeneCQ** — Gene therapy financial exposure modeling; pipeline intelligence expanded in 2025.
- **PSG Modular PBA** — Strategy, procurement and implementation for selectively unbundled pharmacy benefit administration.
- **PBM Audits** — Financial, clinical, rebate, plan-design and implementation reviews.
- **Implementation & Support** — PBM transition project management and operational assistance.
- **Market Research** — Annual pharmacy reports, custom research and research sponsorship opportunities.

## Achievements

- Reported fourth consecutive Inc. 5000 appearance in August 2020.
- Sold its 340B Link business to Omnicell for $225 million in October 2020; this is a business divestiture, not PSG’s current valuation.
- Current homepage reports $10.7 billion in drug cost savings over the last two years; company-reported aggregate.
- Artemetrx Core reports $3 billion in savings identified in 2025; identified opportunities are not necessarily realized savings.

## Latest updates

- **2025-06** — Expanded Artemetrx GeneCQ disease-state modeling and pipeline intelligence.
- **2026-06** — Released drug benefit design research sponsored by Transcarent, surveying 237 benefits leaders.
- **2026-07** — Released the tenth annual specialty spend and trend report, sponsored by CenterWell Pharmacy; 2025 gross specialty trend was 10.8% and net trend 12.5%.

## Links

- Website: https://www.psgconsults.com/
- LinkedIn: https://www.linkedin.com/company/psgconsults
- Twitter/X: https://twitter.com/psgconsults

---

Profile page: https://yespress.io/pharmaceutical-strategies-group
Published by YesPress — https://yespress.io
Last updated: 2026-10-01